
Federica Moschella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3336847/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration. Clinical Cancer Research, 2007, 13, 644-653.	3.2	228
2	Chemotherapy enhances vaccineâ€induced antitumor immunity in melanoma patients. International Journal of Cancer, 2009, 124, 130-139.	2.3	103
3	Identification of Tissue-Restricted Transcripts in Human Islets. Endocrinology, 2004, 145, 4513-4521.	1.4	87
4	Cyclophosphamide Induces a Type I Interferon–Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy. Clinical Cancer Research, 2013, 19, 4249-4261.	3.2	73
5	Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide. Cancer Research, 2011, 71, 3528-3539.	0.4	72
6	Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Annals of the New York Academy of Sciences, 2010, 1194, 169-178.	1.8	64
7	Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. Molecular Oncology, 2012, 6, 1-14.	2.1	48
8	Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use. Cytokine and Growth Factor Reviews, 2015, 26, 121-131.	3.2	43
9	Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. Journal of Translational Medicine, 2015, 13, 139.	1.8	36
10	Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. Cancer Immunology Research, 2018, 6, 658-670.	1.6	34
11	Role of interferon regulatory factor 1 in governing <scp>T</scp> reg depletion, <scp>T</scp> h1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide. International Journal of Cancer, 2018, 142, 976-987.	2.3	32
12	Transcript profiling of human dendritic cells maturation-induced under defined culture conditions: comparison of the effects of tumour necrosis factor alpha, soluble CD40 ligand trimer and interferon gamma. British Journal of Haematology, 2001, 114, 444-457.	1.2	31
13	Nicotinamide inhibits melanoma in vitro and in vivo. Journal of Experimental and Clinical Cancer Research, 2020, 39, 211.	3.5	30
14	Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy. Clinical Cancer Research, 2003, 9, 2022-31.	3.2	27
15	The added value of type I interferons to cytotoxic treatments of cancer. Cytokine and Growth Factor Reviews, 2017, 36, 89-97.	3.2	25
16	The Janus face of cyclophosphamide. Oncolmmunology, 2013, 2, e25789.	2.1	23
17	Modulation of TCR recognition of MHC class II/peptide by processed remote N- and C-terminal epitope extensions. Human Immunology, 2000, 61, 753-763.	1.2	16
18	Exploiting dendritic cells in the development of cancer vaccines. Expert Review of Vaccines, 2013, 12, 1195-1210.	2.0	15

Federica Moschella

#	Article	IF	CITATIONS
19	Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy. Frontiers in Immunology, 2020, 11, 582744.	2.2	9
20	Shifting Gene Expression Profiles During Ex Vivo Culture of Renal Tumor Cells: Implications for Cancer Immunotherapy. Oncology Research, 2003, 14, 133-145.	0.6	7
21	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. Frontiers in Oncology, 2020, 10, 202.	1.3	6
22	MHV-68 producing mIFNα1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68. Vaccine, 2011, 29, 3935-3944.	1.7	5
23	In vitro immunization with a recombinant antigen carrying the HIV-1 RT248–262 determinant inserted at different locations results in altered TCRVB region usage. Human Immunology, 1999, 60, 755-763.	1.2	3
24	Administration of different antigenic forms of altered peptide ligands derived from HIV-1 RTase influences their effects on T helper cell activation. Human Immunology, 2003, 64, 1-8.	1.2	2
25	Recombinant antigens to establish a model of autoimmunity in mice. Transplantation Proceedings, 2001, 33, 57.	0.3	Ο